• 1
    Brodie MJ & Dichter MA. Antiepileptic drugs. N Engl J Med 1996;334:16875.
  • 2
    Koch KM, Wilensky AJ, Levy RH. β-Oxidation of valproic acid, I: effects of fasting and glucose in humans. Epilepsia 1989;30:7829.
  • 3
    Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;2:33272.
  • 4
    Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:659.
  • 5
    Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalised tonic-clonic seizures in adults. N Engl J Med 1992;327:76571.
  • 6
    Gidal BE, Anderson GD, Spencer NW, et al. Valproate-associated weight gain: potential relation to energy expenditure and metabolism in patients with epilepsy. J Epilepsy 1996;9:23441.
  • 7
    Rättyä J, Vainionpää L, Knip M, et al. The effects of valproate, carbamazepine and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103:58893.
  • 8
    Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45:44450.DOI: 10.1002/1531-8249(199904)45:4<444::aid-ana5>;2-6
  • 9
    Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:13838.
  • 10
    Isojärvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:57984.
  • 11
    Herzog AG. Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic? Ann Neurol 1996;39:55960.
  • 12
    Isojärvi JI, Rättyä J, Myllalä VV, et al. Valproate, lamotrigine and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:44651.
  • 13
    Hopkinson ZE, Sattar N, Fleming R, et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. Br Med J 1998;317:32932.
  • 14
    Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:85361.
  • 15
    Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinaemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988;50:197212.
  • 16
    Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol 1990;32:21320.
  • 17
    Kuczmarski RJ, Carroll MD, Flegal KM, et al. Varying body mass index cutoff points to describe overweight prevalence among US adults: NHANES III (1988 to 1994). Obesity Res 1997;5:5428.
  • 18
    Balen A. Pathogenesis of polycystic ovary syndrome: the enigma unravels? Lancet 1999;354:9667.
  • 19
    Polson DW, Wadsworth J, Adams J, et al. Polycystic ovaries: a common finding in normal women. Lancet 1988;ii:8702.
  • 20
    Fox R, Corrigan E, Thomas PA, et al. The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests. Clin Endocrinol 1991;34:12731.
  • 21
    Sheu WH, Hsu CH, Chen YS, et al. Prospective evaluation of insulin resistance and lipid metabolism in women receiving oral contraceptives. Clin Endocrinol 1994;40:24955.
  • 22
    Bridsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterisation. Ann Intern Med 1997;126:325
  • 23
    Bhasin S, Bagatell CJ, Bremner WJ, et al. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998;83:34358.
  • 24
    Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovarian syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:270512.
  • 25
    Bardin CW & Lipsett MB. Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 1967;46:891902.
  • 26
    Mahoudeau JA, Bardin CW, Lipsett MB. The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the Δ5-androstanediols. J Clin Invest 1971;50:133844.
  • 27
    Chang RJ, Laufer LR, Meldrum DR, et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotrophin-releasing hormone agonist. J Clin Endocrinol Metab 1983;56:897903.
  • 28
    Rittmaster RS, Deshwal N, Lehman L. The role of adrenal hyperandrogenism, insulin resistance and obesity in the pathogenesis of polycystic ovarian syndrome. J Clin Endocrinol Metab 1993;76:1295300.
  • 29
    Ciaraldi TP, El-Roeiy A, Madar Z, et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992;75:57783.
  • 30
    Buffington CK & Kitabchi AE. Evidence for a defect in insulin metabolism in hyperandrogenic women with polycystic ovarian syndrome. Metabolism 1994;43:136772.
  • 31
    Conway GS & Jacobs HS. Clinical implications of hyperinsulinaemia in women. Clin Endocrinol 1993;39:62332.
  • 32
    Dunaif A. Insulin resistance and the polycystic ovarian syndrome: mechanisms and implication for pathogenesis. Endocr Rev 1997;18:774800.
  • 33
    Walker M. Obesity, insulin resistance and its links to non-insulin-dependent diabetes mellitus. Metab Clin Exp 1995;44(suppl 3):1820.
  • 34
    Bauer J, Jarre A, Klingmüller D, et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000;41:1637.
  • 35
    MacPhee GJ, Larkin JG, Butler E, et al. Circulating hormones and pituitary responsiveness in young men receiving long-term antiepileptic medication. Epilepsia 1988;29:46875.
  • 36
    Isojärvi JI, Pakarinen AJ, Ylipalosaari PJ, et al. Serum hormones in male patients receiving anticonvulsant medication. Arch Neurol 1990;47:6706.
  • 37
    Cramer JA & Jones EE. Reproductive function in epilepsy. Epilepsia 1991;32(suppl 6):1926.
  • 38
    Herzog AG. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology 1993;43:19079.
  • 39
    Nappi C, Meo R, Di Carlo C, et al. Reduced fertility and neuroendocrine dysfunction in women with epilepsy. Gynaecol Endocrinol 1994;8:13345.
  • 40
    Cummings LN, Giudice L, Morrell M. Ovulatory function in epilepsy. Epilepsia 1995;36:3559.
  • 41
    Stoffel-Wagner B, Bauer J, Flügel D, et al. Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia 1998;39:116473.